QDEL Insider Trading

Insider Ownership Percentage: 1.00%
Insider Buying (Last 12 Months): $249,886.86
Insider Selling (Last 12 Months): $374,367,521.97

QuidelOrtho Insider Trading History Chart

This chart shows the insider buying and selling history at QuidelOrtho by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$200M$0$200MTotal Insider BuyingTotal Insider Selling

QuidelOrtho Share Price & Price History

Current Price: $25.17
Price Change: Price Decrease of -0.1 (-0.40%)
As of 04/17/2025 05:00 PM ET

This chart shows the closing price history over time for QDEL up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$25.17Closing price on 04/17/25:

SEC Filings (Institutional Ownership Changes) for QuidelOrtho (NASDAQ:QDEL)

99.00% of QuidelOrtho stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at QDEL by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$12Mbought$222ksoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$400M-$200M$0$200M$400MTotal InflowsTotal Outflows
QuidelOrtho logo
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
Read More on QuidelOrtho

Today's Range

Now: $25.17
Low: $24.44
High: $25.45

50 Day Range

MA: $35.42
Low: $25.17
High: $41.96

52 Week Range

Now: $25.17
Low: $24.44
High: $49.45

Volume

938,597 shs

Average Volume

989,274 shs

Market Capitalization

$1.70 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.43

Who are the company insiders with the largest holdings of QuidelOrtho?

QuidelOrtho's top insider shareholders include:
  1. Carlyle Group Inc (Major Shareholder)
  2. Brian J Blaser (CEO)
  3. Joseph M Busky (CFO)
Learn More about top insider investors at QuidelOrtho.

Who are the major institutional investors of QuidelOrtho?

QuidelOrtho's top institutional investors include:
  1. Assenagon Asset Management S.A. — 0.46%
  2. Rhumbline Advisers — 0.19%
  3. GAMMA Investing LLC — 0.13%
  4. Wealth Enhancement Advisory Services LLC — 0.11%
  5. Wedge Capital Management L L P NC — 0.10%
  6. Moody National Bank Trust Division — 0.07%
Learn More about top institutional investors of QuidelOrtho stock.

Which institutional investors are selling QuidelOrtho stock?

In the last quarter, QDEL stock was sold by these institutional investors:
  1. Wedge Capital Management L L P NC

Which institutional investors are buying QuidelOrtho stock?

Within the last quarter, QDEL stock was purchased by institutional investors including:
  1. Assenagon Asset Management S.A.
  2. GAMMA Investing LLC
  3. Wealth Enhancement Advisory Services LLC
  4. Pallas Capital Advisors LLC
  5. Merit Financial Group LLC
  6. Moody National Bank Trust Division
  7. Rhumbline Advisers
  8. Yousif Capital Management LLC
Within the last year, these company insiders have bought QuidelOrtho stock:
  1. Carlyle Group Inc (Major Shareholder)
  2. Brian J Blaser (CEO)
Learn More investors buying QuidelOrtho stock.